| 1 |
35165514 | Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. | 2022 |
1 |
| 2 |
28060183 | Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells. | 2017 Feb |
2 |
| 3 |
28537897 | MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). | 2017 Jul 18 |
1 |
| 4 |
28581516 | Pancreatic cancer heterogeneity and response to Mek inhibition. | 2017 Oct 5 |
1 |
| 5 |
25376606 | Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. | 2015 Jan |
1 |
| 6 |
25946136 | Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. | 2015 |
1 |
| 7 |
26228206 | The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). | 2015 Dec 15 |
1 |
| 8 |
24819705 | HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. | 2014 Jul |
1 |
| 9 |
24966685 | Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways. | 2014 |
1 |
| 10 |
23091117 | Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. | 2013 Jan 1 |
2 |
| 11 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
1 |
| 12 |
23320839 | MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. | 2013 Jan 15 |
2 |
| 13 |
22797388 | New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma. | 2012 Jul 10 |
1 |
| 14 |
22110196 | Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. | 2011 Nov |
3 |
| 15 |
18049840 | Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. | 2008 Feb |
1 |
| 16 |
18813828 | The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. | 2008 Oct |
1 |
| 17 |
16307741 | Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells. | 2005 Dec 5 |
1 |